Group 1: Company Overview - The company is Zhejiang Xinhacheng Co., Ltd., with stock code 002001 and abbreviation Xinhacheng [1] - The investor relations activity was recorded under number 2025-014 [1] Group 2: Investor Relations Activity - The activity included a strategy meeting with various investment firms and analysts [2] - Key participants included representatives from Guosen Securities, Qianhai Hezhi, and Huaxia Fund among others [2] Group 3: Project Updates - The Tianjin Nylon New Materials project commenced pile foundation construction in September 2025 and is expected to be completed by 2027 [3] - The company has a solid methionine production capacity of 30,000 tons, with an expansion project of 70,000 tons nearing completion [3] - The Heilongjiang base focuses on bio-fermentation products, including Vitamin C and various amino acids, enhancing overall efficiency through technological upgrades [3] Group 4: New Materials and Product Development - The company aims to be a leader in the new materials sector, focusing on high-performance polymers like PPS, with a current capacity of 22,000 tons and plans for expansion [4] - The fragrance segment produces various products, including linalool and citral, with ongoing projects to enhance product offerings [4] Group 5: Future Plans and Strategic Focus - The company plans to focus on health and high polymer new materials, emphasizing integrated and collaborative development strategies [6] - A share buyback plan is in place, with a total amount of 300 million to 600 million yuan allocated for stock repurchase to enhance investor confidence [6]

Financial Performance - In Q3 2025, the company achieved a revenue of 166.42 billion CNY, with a net profit attributable to shareholders of 55.41 billion CNY, reflecting a year-on-year revenue growth of 5.45% and a net profit increase of 33.37% [3] - The company has maintained steady growth through production and sales linkage, market expansion, and cost control measures [3] Product Development and Market Strategy - The company focuses on the "Chemical+" and "Biological+" strategies, targeting opportunities in nutrition products, new materials, flavoring agents, and active pharmaceutical ingredients [3] - In the human nutrition sector, the company offers a range of products including vitamins A, D3, E, C, coenzyme Q10, taurine, β-carotene, and lycopene, with a commitment to customized formulations for various applications [3] - The solid methionine production capacity is currently at 30,000 tons, with an expansion project underway [3] Strategic Partnerships and Projects - The company has partnered with Sinopec to establish a joint venture for a liquid methionine project, with a production capacity of 18,000 tons/year [3] - The nylon new materials project in Tianjin has commenced construction, focusing on an integrated production chain from adiponitrile to nylon 66 [4] Future Plans and Innovations - The company aims to enhance its core competitiveness in the new materials sector by developing high-performance polymers and key intermediates [4] - The company is expanding its flavor and fragrance segment, with plans for a new fragrance industrial park in Shandong [4] - The Heilongjiang base is focused on bio-fermentation products, with ongoing improvements in product lines and operational efficiency [4] International Expansion - Over 50% of the company's sales are from international markets, with established subsidiaries in regions including Hong Kong, Singapore, Germany, Mexico, Brazil, Japan, and Vietnam [6] - The company emphasizes overseas market expansion as part of its 2025 operational strategy [6] Employee Engagement and Incentives - The company is implementing a share buyback program with a total amount between 30 million to 360 million CNY, aimed at employee stock ownership plans to enhance motivation and align interests [6]